Faeth reports Q3 loss as FDA grants Fast Track status to PIKTOR
+2 new sources since this summary was written
Faeth Therapeutics released third-quarter 2026 results on November 3 and said the FDA granted Fast Track designation to PIKTOR with paclitaxel for certain advanced or recurrent endometrial cancer patients. The company expects initial Phase 2 PIK-201 endometrial cancer results by year-end, while reporting $174.8 million in cash, cash equivalents and marketable securities at September 30, 2026. Quarterly net loss was $20.4 million, or $0.79 per basic and diluted share.
Why it matters
The FDA designation may support expedited development and review of Faeth's lead program for an identified endometrial cancer population. Faeth expects a potentially important clinical data readout by year-end, while its higher quarterly expenses and net loss show continued cash use.
Key facts
- 1The FDA granted Fast Track designation to PIKTOR combined with paclitaxel for advanced or recurrent endometrial cancer with a PAM-pathway alteration after prior platinum chemotherapy and an immune checkpoint inhibitor. sec.gov
- 2Faeth said topline results from the Phase 2 PIK-201 endometrial cancer study are expected by year-end 2026. sec.gov
- 3Cash, cash equivalents and marketable securities totaled $174.8 million at September 30, 2026, versus $21.2 million at December 31, 2025. sec.gov
- 4Third-quarter 2026 research and development expense was $11.7 million, while general and administrative expense was $10.4 million. sec.gov
- 5For the quarter through September 30, 2026, Faeth recorded a net loss of $20.4 million, equal to $0.79 per basic and diluted share. sec.gov
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.